TransCode Therapeutics (RNAZ) Competitors $9.10 +0.38 (+4.36%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. ENLV, COEP, TPST, NRSN, CVKD, CGTX, ALXO, CARA, TENX, and OVIDShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Enlivex Therapeutics Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Tenax Therapeutics Ovid Therapeutics Enlivex Therapeutics (NASDAQ:ENLV) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Which has more volatility and risk, ENLV or RNAZ? Enlivex Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Which has higher earnings and valuation, ENLV or RNAZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.88TransCode TherapeuticsN/AN/A-$16.75MN/AN/A Do insiders & institutionals have more ownership in ENLV or RNAZ? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ENLV or RNAZ? In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 1 articles in the media. TransCode Therapeutics' average media sentiment score of 1.89 beat Enlivex Therapeutics' score of 1.87 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Enlivex Therapeutics Very Positive TransCode Therapeutics Very Positive Is ENLV or RNAZ more profitable? Enlivex Therapeutics' return on equity of -57.67% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% TransCode Therapeutics N/A -578.88%-222.61% Do analysts recommend ENLV or RNAZ? Enlivex Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 706.45%. TransCode Therapeutics has a consensus target price of $280.00, indicating a potential upside of 2,976.92%. Given TransCode Therapeutics' higher probable upside, analysts plainly believe TransCode Therapeutics is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEnlivex Therapeutics beats TransCode Therapeutics on 8 of the 11 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.55M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E RatioN/A9.1628.6119.64Price / SalesN/A735.94437.49188.30Price / CashN/A164.3436.0257.93Price / Book-0.174.688.185.63Net Income-$16.75M$30.99M$3.23B$257.73M7 Day Performance-0.33%0.57%-0.25%0.07%1 Month Performance24.66%7.91%5.40%8.32%1 Year Performance-99.97%-5.94%26.35%13.78% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.7354 of 5 stars$9.10+4.4%$280.00+2,976.9%-100.0%$7.55MN/A0.009Positive NewsGap UpENLVEnlivex Therapeutics2.8334 of 5 stars$1.21+2.5%$10.00+726.4%-12.8%$27.91MN/A-1.8370COEPCoeptis Therapeutics0.5043 of 5 stars$7.73+2.5%N/A+62.4%$26.49M$62.87K-1.332News CoverageTPSTTempest Therapeutics2.3472 of 5 stars$7.08-0.7%$30.00+323.7%-76.8%$26.26MN/A-0.3920NRSNNeuroSense Therapeutics2.4624 of 5 stars$2.09+9.4%$14.00+569.9%+114.3%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.9296 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics2.9157 of 5 stars$0.58+42.9%$2.83+389.5%-70.4%$25.11MN/A-0.7820News CoverageGap UpHigh Trading VolumeALXOALX Oncology3.54 of 5 stars$0.44-3.5%$3.30+643.2%-94.2%$24.57MN/A-0.1840CARACara Therapeutics0.2157 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.6574 of 5 stars$5.75-1.0%$17.50+204.3%+77.1%$24.10MN/A-2.329Positive NewsOVIDOvid Therapeutics4.636 of 5 stars$0.37+10.5%$3.13+735.6%-60.8%$24.06M$570K-1.0760Gap DownHigh Trading Volume Related Companies and Tools Related Companies Enlivex Therapeutics Competitors Coeptis Therapeutics Competitors Tempest Therapeutics Competitors NeuroSense Therapeutics Competitors Cadrenal Therapeutics Competitors Cognition Therapeutics Competitors ALX Oncology Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Ovid Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts